Lanean...
Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
Resistance to tamoxifen is a clinically major challenge in breast cancer treatment. Although downregulation of estrogen receptor‐alpha (ERα) is the dominant mechanism of tamoxifen resistance, the reason for ERα decrease during tamoxifen therapy remains elusive. Herein, we reported that Spalt‐like tr...
Gorde:
| Argitaratua izan da: | EMBO Mol Med |
|---|---|
| Egile Nagusiak: | , , , , , , , , , , , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley and Sons Inc.
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6895605/ https://ncbi.nlm.nih.gov/pubmed/31657150 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201910638 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|